Tumour budding with and without admixed inflammation: Two different sides of the same coin?

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 368-371

  Max, Nicole ^a   Harbaum, Lars ^b   Pollheimer, Marion J ^a   Lindtner, Richard A ^c   Kornprat, Peter ^a   Langner, Cord ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

colorectal cancer; epithelial mesenchymal transition; inflammation; multivariate logistic regression; prognosis; survival; tumour budding

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL INVASION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR BUDDING; TUMOR GROWTH; TUMOR VOLUME; COLORECTAL TUMOR; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 84954357581     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.454     Document Type: Article

References (23)

1. Betge J, Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Vieth M, Langner C. (2012). Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 19: 3706-3712.
2. Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. (2007). Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis. 22: 863-868.
3. Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, Lugli A, Zlobec I. (2014). The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 64: 577-584.
4. Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Bokemeyer C, Langner C. (2015). Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol. 28: 403-413.
5. Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, Lugli A. (2013). Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 44: 697-705.
6. Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, Watanabe M. (2008). Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 10: 41-47.
7. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, Lugli A. (2013). Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 26: 295-301.
8. Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ. (2005). Inflammation and prognosis in colorectal cancer. Eur J Cancer. 41: 2645-2654.
9. Koelzer VH, Dawson H, Andersson E, Karamitopoulou E, Masucci GV, Lugli A, Zlobec I. (2015). Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. Transl Res. 166: 207-217.
10. Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson H, Dirschmid K, Hädrich M, Inderbitzin D, Offner F, Puppa G, Seelentag W, Schnüriger B, Tornillo L, Lugli A. (2015). Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 466: 485-493.
11. Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, Iezzi G, Spagnoli G, Bihl M, Terracciano L, Zlobec I. (2009). CD8 lymphocytes/tumour-budding index: an independent prognostic factor representing a ?pro-/anti-Tumour? approach to tumour host interaction in colorectal cancer. Br J Cancer. 101: 1382-1392.
12. Lugli A, Karamitopoulou E, Zlobec I. (2012). Tumour budding: a promising parameter in colorectal cancer. Br J Cancer. 106: 1713-1717.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 93: 387-391.
14. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. (2012). Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 25: 1315-1325.
15. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322: 352-358.
16. Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H, Mukogawa T, Nakagawa T, Uchimoto K, Nakamura S, Nonomura A, Nakajima Y. (2008). Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 28: 1831-1836.
17. Prall F. (2007). Tumour budding in colorectal carcinoma. Histopathology. 50: 151-162.
18. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. (2009). Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer. 45: 2138-2145.
19. Shinto E, Jass JR, Tsuda H, Sato T, Ueno H, Hase K, Mochizuki H, Matsubara O. (2006). Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 49: 1422-1430.
20. Sobin L, Gospodarowicz MK, Wittekind C (eds). (2010). TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell: West Sussex, UK.
21. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. (2002). Tumour ?budding? as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 40: 127-132.
22. Zlobec I, Lugli A. (2010). Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 1: 651-661.
23. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. (2012). The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology. 61: 777-787.